

References

(A)

- Abrams JR, Kelley SL, Hayes E, Kikuchi T and Brown MJ (2003):** Blockade of T lymphocyte co-stimulation with cytotoxic T lymphocyte associated antigen 4 immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques including the activation of keratinocytes, dendritic cells and endothelial cells. *J Exp Med*; 192: 681-93.
- Ackermann L, Harvima IT and Pelkonen J (1999):** Mast cells in psoriatic skin are strongly positive for interferon-gamma. *Br J Dermatol*; 140: 624-33.
- Akman A, Dicle O, Yilmaz F and Coskun M (2008):** Discrepant levels of vascular endothelial growth factor in psoriasis patients treated with PUVA, Re- PUVA and narrow-band UVB. *Photodermatol Photoimmunol Photomed*; 24: 123–127.
- Altmann EM and Kamino H (1999):** Diagnosis: psoriasis or not? What are the clue? *Semin Cut Med Surg*; 18: 25-35.
- Andrys C, Borska L and Pohl D (2007):** Angiogenic activity in patients with psoriasis is significantly decreased by Goeckerman's therapy. *Arch Dermatol Res*; 298: 479–483.
- Armstrong AW, Armstrong EN, Fuller ME and Sockolov SV (2011):** Smoking and Pathogenesis of Psoriasis. A Review of Oxidative, Inflammatory and Genetic Mechanisms. *Br J Dermatol*; 165(6):1162-1168.

(B)

- Balato A, Balato N, Megna M, Schiattarella M, Lembo S and Ayala F (2012):** Pathogenesis of Psoriasis: The Role of Pro-Inflammatory Cytokines Produced by Keratinocytes. *Psoriasis*; 2:9-28.
- Bandow GD and Koo JYM (2004):** Narrow-band ultraviolet B radiation: a review of the current literature. *Int. J. Dermatol*, 43: 555-561.
- Barile S, Medda E and Nistico` (2006):** Vascular endothelial growth factor gene polymorphisms increase the risk to develop psoriasis. *Exp Dermatol*; 15: 368–376.
- Bates DO and Curry FE (1997):** Vascular endothelial growth factor increases microvascular permeability via a $\text{Ca}^{(2+)}$ -dependent pathway. *Am. J. Physiol.*; 273: H687-H694.
- Berneburg M, Ro`cken M and Bendixf N (2005):** Phototherapy with Narrowband vs. Broadband UVB *Acta. Derm. Venereol*; 85: 98-108.
- Bhushan M, McLaughlin B, Weis JB and Griffiths CEM (1999):** Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. *Br J Dermatol* ; 141: 1054–1060.
- Biedermann T, Kneilling M and Mailhammer R (2000):** Mast cells control neutrophil recruitment during T cell–mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2; *J Exp Med*; 192:1441-52.

Bos JD, De Rie M, Teunissen M and Piskin G (2005): Psoriasis: dysregulation of innate immunity. *Br J Dermatol*; 152: 1098-1107.

Bowcock A and Krueger J (2005): Getting under the skin: the immunogenetics of psoriasis. *Nat Rev Immunol*; 5: 699-711.

(C)

Cai Y, Fleming C and Yan J (2012): New insights of T cells in the pathogenesis of psoriasis. *Cell Mol Immunol.* ;9(4):302-9.

Callen JP, Krueger GG, Lebwohl M, McBurney EI, Mease P, Menter A, Paller AS, Pariser DM, Weinblatt M and Zimmerman G. (2003): AAD consensus statement on psoriasis therapies. *J Am Acad Dermatol*; 49(5):897-899.

Campalani E and Barker J (2005): The clinical genetics of psoriasis. *Curr Genom*; 6: 51-60.

Canavese M, Altruda F, Ruzicka T, Schaubert J (2010): Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis—A possible target for novel therapies?. *J Dermatol Sci*;58(3):171-6.

Capon F, Helms C, Veal CD, Tillman D, Burden AD, Barker JN, Bowcock AM, and Trembath RC (2004): Genetic analysis of psors2 markers in a uk dataset supports the association between raptor snps and familial psoriasis. *J Med Genet*, 41(6):459-60.

- Carlin CS, Feldman SR, Krueger JG, Menter A and Krueger GG (2004):** A 50% reduction in the Psoriasis Area and Severity Score (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. *J Am Acad Dermatol*; 50:859–66.
- Carmeliet P. (2000):** Mechanisms of angiogenesis and arteriogenesis. *Nat. Med*; 6:389–395.
- Carmeliet P (2003):** Angiogenesis in health and disease. *Nat. Med.*; 9: 653–660.
- Cébe-Suarez S, Zehnder-Fjällman A and Ballmer-Hofer K (2006):** The role of VEGF receptors in angiogenesis; complex partnerships, *Cell. Mol. Life Sci*; 63:601–615.
- Chaudhari PR, Stern DK and Lebwohl MG (2008):** Treatment of psoriasis. *Milestones in drug therapy*; 0:41-55.
- Chiricozzi A and Chimenti S (2012):** Effective topical agents and emerging perspectives in the treatment of psoriasis. *Expert Rev Dermatol*; 7(3):283-293.
- Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P and Santos-Silva A (2012):** The roles of cells and cytokines in the pathogenesis of psoriasis. *Int J Dermatol* ; 51(4):389-95.
- Creamer D, Allen M, Jaggar R, Stevens R, Bicknell R and Barker J (2002):** Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. *Arch Dermatol*; 138:791–796.
- Curry JL, Qin J, Bonish B, Carrick R, Bacon P and Panella J (2003):** Innate immune-related receptors in normal and psoriatic skin. *Arch Pathol Lab Med*; 127: 178-185.

(D)

- Dai Hui and Xu Ai-E (2012):** The vascular features of psoriatic skin: imaging using in vivo confocal laser scanning microscopy. *Skin Research and Technology*;0:1-4.
- De Rie MA, Goedkoop AY and Bos JD (2004):** Overview of psoriasis. *Dermatol Ther*; 17: 341-349.
- Del Rosso J and Friedlander S (2005):** Corticosteroids: Options in the era of steroid-sparing therapy. *J. Am. Acad. Dermatol* ; 53: 50-58.
- Detmar M, Brown LF and Claffey KP (1994):** Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. *J. Exp. Med*;180:1141–1146.
- Dumont DJ, Jussila L and Taiale (1998):** Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. *Science*; 282-940.
- Dvorak HF (2002):** Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. *J Clin Oncol*; 20: 4368-80.

(E)

- Elias PM, Arbiser J and Brown BE (2008):** Epidermal vascular endothelial growth factor production is required for permeability barrier homeostasis, dermal angiogenesis, and the development of epidermal hyperplasia: implications for the pathogenesis of psoriasis. *Am. J. Pathol.*; 173: 689–699.

(F)

- Feldman SR (2003):** The design of clinical trials in psoriasis lessons for clinical practice. *J Am Acad Dermatol*; 49:S62–S65.
- Feldman SR and Krueger GG (2005):** Psoriasis assessment tools in clinical trials. *Ann Rheum Dis*; 64(II): 65–68.
- Feldman SR, Sangha ND and Setaluri V (2000):** Topical corticosteroid in foam vehicle offers comparable coverage compared with traditional vehicles. *J Am Acad Dermatol* in ; 42(6):1017-1020.
- Feldman SR, Lapolla W, Yentzer BA, Christian R and Halvorson BA (2011):** A review of phototherapy protocols for psoriasis treatment *J Am Acad Dermatol*; 64(5) : 936-949.
- Ferrandiz C, Pujol RM, Garcia-Patos V, Bordas X and Smandia JA (2002):** Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. *J Am Acad Dermatol*; 46: 867-873.
- Ferrara N , Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Gerber HP, KikkawaY, Miner JH and Quaggin SE (2003):** Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. *J Clin Invest*; 111:707–716.
- Fink AM, Cauza E and Hassfeld W (2007):** Vascular endothelial growth factor in patients with psoriatic arthritis. *Clin Exp Rheumatol*; 25: 305–308.

- Flisiak I, Mys'liwiec H and Chodyncka B (2005):** Effect of psoriasis treatment on plasma concentrations of metalloproteinase-1 and tissue inhibitor of metalloproteinases-1. *J Europ Acad Dermatol Venereol*; 19: 418–421.
- Flisiak I, Zaniewski P and Chodyncka B (2008):** Plasma TGF- β 1, TIMP-1, MMP-1 and IL-18 as combined biomarker of psoriasis activity. *Biomarkers*; 13: 549–556.
- Flisiak I, Zaniewski P, Rogalska-Taranta M and Chodyncka B (2011):** Effect of psoriasis therapy on VEGF and its soluble receptors serum concentrations. *J Europ Acad Dermatol Venereol*; 26(3):302–307.
- Forsythe P and Bienenstock J (2012):** The Mast Cell- Nerve Functional Unit: A Key Component of Physiologic and Pathophysiologic Responses. *Chem Immunol Allergy*; 98: 196–221
- Fredriksson T and Pettersson U (1978):** Severe psoriasis—oral therapy with a new retinoid. *Dermatologica*; 157:238–44.

(G)

- Gaspari AA (2006):** Innate and adaptive immunity and the pathophysiology of psoriasis. *J Am Acad Dermatol.*; 54(3):67-80.
- Gerber HP and Ferrara N (2002):** Vascular endothelial growth factor regulates hematopoietic stem cell survival by an internal autocrine loop mechanism. *Nature*; 417: 954-958.
- Gerber HP, Dixit V and Ferrara N (1998):** Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. *J. Biol. Chem*; 273: 13313-13316.

- Gerber W, Arheilger B and Ha TA (2003):** Ultraviolet B 308-nm excimer laser treatment of psoriasis: a new phototherapeutic approach. *Br J Dermatol*; 149:1250.
- Ghoreschi K, Weigert C and RöckenM (2007):** Immunopathogenesis and role of T cells in psoriasis. *Clinic Dermatol*; 25(6): 574-580.
- Gibbs NK (2003):** Narrowband UV-B phototherapy clears psoriasis through a combination of local and systemic effects. *Arch. Dermatol*; 139: 665-666.
- Godié A (2004):** New approaches to psoriasis treatment: A review. *Acta Dermatoven APA*; 13 (2): 50-58.
- Goodfield M, Kownacki S and Berth-Jones J (2004):** Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex) with a 5% coal tar preparation (Alphosyl) in chronic plaque psoriasis. *J Dermatolog Treat*; 15:14.
- Goodless D (2008):** Topical Anthralin is still useful in psoriasis treatment. *J Dermatol. Treat*; 18: 23-25
- Gordon KB and Ruderman EM (2006):** The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. *J Am Acad Dermatol* ; 54(3): 85-91.
- Gottlieb AB, Chaudhari U, Baker DG, Perate M and Dooley LT (2003):** The National Psoriasis Foundation Psoriasis Score (NPF-PS) system versus the Psoriasis Area Severity Index (PASI) and Physician's Global Assessment (PGA): a comparison. *J Drugs Dermatol*; 2:260–265.

Griffiths CE and Barker JN (2007): Pathogenesis and clinical features of psoriasis. *Lancet*; 370(9583): 263-271.

Guérard S and Pouliot R (2012): The Role of Angiogenesis in the Pathogenesis of Psoriasis: Mechanisms and Clinical Implications): *J Clin Exp Dermatol Res*; 4:002.

Gudjonsson JE, Johnston A, Sigmundsdottir H and Valdimarsson H (2004): Immunopathogenic mechanisms in psoriasis. *Clin Exp Immunol*; 135:1-8.

Gudmundsdottir AS, Sigmundsdottir H, Sigurgeirsson B, Good MF, Valdimarsson H and Jonsdottir I (1999): Is an epitope on keratin 17 a major target for autoreactive T lymphocytes in psoriasis?. *CLIN EXP IM*; 117(3): 580-586.

(H)

Harper SJ and Bates DO (2008): VEGF-A splicing: the key to anti-angiogenic therapeutics? *Nat. Rev. Cancer*; 8: 880–887.

Hattori K (2001): Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. *J. Exp Med.*; 193: 1005-1014.

Hecker D and Lebwohl M (1997): Topical calcipotriene in combination with UVB phototherapy for psoriasis. *Int J Dermatol*; 36 (4):302-303.

Heidenreich R, Rocken M and Ghoreschi K (2008): Angiogenesis; the new potential target for the therapy of psoriasis?. *Drug News Perspect*;21:97–105.

- Heidenreich R, Röcken M and Ghoreschi K (2009):** Angiogenesis drives psoriasis pathogenesis. *International Journal of Experimental Pathology*; 90(3): 232–248.
- Henno A, Blacher S and Lambert C (2009):** Altered expression of angiogenesis and lymphoangiogenesis markers in the uninvolved skin of plaque-type psoriasis. *Br J Dermatol*; 160(3):581–590.
- Higgins E (2000):** Alcohol, smoking and psoriasis. *Clin Exp Dermatol*; 25: 107-110.
- Hood JD, Meininger CJ, Ziche M and Granger HJ (1998):** VEGF upregulates NO production in human endothelial cells. *Am. J. Physiol.*; 274: 1054–1058.
- Housman TS, Rohrbek JM and Fleischer ABJ (2002):** Phototherapy utilization for psoriasis is declining in the United States. *J. Am. Acad. Dermatol.*, 46: 57-59.

(J)

- Jappe U (2000):** Superantigens and their association with dermatological inflammatory diseases: facts and hypotheses. *Acta Derm Venereol*; 80(5):321-8.
- Jeltsch M, Kaipainen A, Joukov V, Meng XJ, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK and Alitalo K (1997):** Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. *Science*; 276: 1423-1425.
- Jiang BH, Agani F, Passaniti A and Semenza GL (1997):** Hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding

vascular endothelial growth factor and enolase 1: Involvement of HIF-1 in tumor progression. *Cancer Res.*; 57: 5328–5335.

Jonca F, Ortega N, Gleizes PE, Bertrand N and Plouet J (1997): Cell release of bioactive fibroblast growth factor 2 by exon 6'-encoded sequence of vascular endothelial growth factor. *J. Biol. Chem.*; 272: 24203–24209.

(K)

Kanazawa N (2012): Rare hereditary autoinflammatory disorders: Towards an understanding of critical in vivo inflammatory pathways. *J. Dermatol. Sci.*; 66 (3): 183–189.

Kanno S, Oda N and Abe M (2000): Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells. *Oncogene* ;19:2138–2146.

Keaney TC and Kirsner RS (2010): New insights into the mechanism of narrow-band UVB therapy for psoriasis. *J Invest Dermatol.*; 130(11):2534.

Kendall RL, Wang G and Thomas KA (1996): Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1 and its heterodimerization with KDR. *Biochem Biophys Res Commun.*; 226: 324–328.

Kess D, Peters T and Zamek J (2003): CD4⁺ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. *J Immunol.*; 171:5697-706.

- Koch S, Koh IK and Klein E (2006):** Skin homing of Langerhans cell precursors: Adhesion, chemotaxis, and migration. *J. Allergy Clin. Immunol*; 117: 163-168.
- Kozub P and Simaljakova M (2011):** Systemic therapy of psoriasis: methotrexate. *Bratisl Lek Listy*;112(7):390-4.
- Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P and Heftler NS (1995):** Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. *J Exp Med*; 182:2057–68.
- Kumar U, Kaur I, Dogra S, De D and Kumar B (2010):** Topical tazarotene vs. coal tar in stable plaque psoriasis, *Clinical and Experimental Dermatology*; 35 (5): 482–486.

(L)

- Lam J, Polifka JE and Dohil MA (2008):** Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases. *J Am Acad Dermatol*; 59:295.
- Langley RG and Ellis CN (2005):** Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. *J Am Acad Dermatol*;51:563–9.
- Lebwohl M (2003):** Psoriasis. *Lancet*; 361: 1197-204.

- Lebwohl M and Ali S (2001):** Treatment of psoriasis. Part 1. Topical therapy and phototherapy. *J Am Acad Dermatol*; 45:487
- Leker RR, Teichner A, Ovadia H, Keshet E, Reinherz E and Ben Hur T (2001):** Expression of endothelial nitric oxide synthase in the ischemic tissue; relationship to expression of neuronal nitric oxide synthases and vascular endothelial growth factor. *Brain Res.*; 909: 1-7.
- Levine RJ, Maynard SE and Qian C (2004a):** Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. *J. Biol. Chem*; 273: 11197–11204.
- Levine RJ, Maynard SE and Qian C (2004b):** Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. *J. Clin. Invest*; 111: 649–658.
- Levy NS, Chung S, Furneaux H and Levy AP (1998):** Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. *J. Biol. Chem*; 273: 6417–6423.
- Louden BA, Pearce DJ, lang Wei and Feldman SR (2004):** A simplified psoriasis area severity index (SPASI) for rating psoriasis severity in clinic patients. *Dermatology Online Journal* ; 10 (2): 7.
- Lucka TC, Pathirana D, Sammain A, Bachmann F, Rosumeck S and Erdmann R (2012) :** Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. *J Eur Acad Dermatol Venereol*; 10:124-126.

- Luo S, Zheng Y, and Peng Z (2008a):** Effects of narrow-band ultraviolet B and tazarotene therapy on keratinocyte proliferation and TIG3 expression. *J. Dermatol.*, 35: 651-7.
- Luo S, Zheng Y, Zeng WH, Peng Z, Tan S and Xi Y (2008b):** Alteration of tazarotene induced gene-2 expression in psoriasis vulgaris, *Nan Fang Yi Ke Da Xue Xue Bao* ; 28(10):1792-4.

(M)

- Makinen T, Jussila L and Veikkola T (2001a):** Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. *Nat. Med*; 7, 199–205.
- Makinen T, Veikkola T and Mustjoki S (2001b):** Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. *EMBO J*; 20:4762–4773.
- Man X, Yang X, Cai S, Yao Y and Zheng M (2006):** Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. *Mol. Med*; 12; 127–136.
- Martin D, Towne J, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG and Russell CB (2012):** The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings. *J Invest Dermatol*; 35(11):1789-98.
- Martin G, Guérard S, Fortin MR, Rusu D, Soucy J, Poubelle PE and Pouliot R (2012):** Pathological crosstalk in vitro between

- T lymphocytes and lesional keratinocytes in psoriasis: necessity of direct cell-to-cell contact. *Laboratory Investigation* ;92: 1058-1070. .
- Mason AR, Mason J, Cork M and Dooley G (2009):** Topical treatments for chronic plaque psoriasis. *Cochrane Database Syst. Rev*; 15: CD005028.
- Mathonnetm G, Leger C and Desnoyers J (2003):** UV wavelength-dependent regulation of transcription-coupled nucleotide excision repair in p53-deficient human cells. *Proc . Natl. Acad. Sci. U SA*; 100: 7219-7224.
- Matsumoto T and Claesson-Welsh L (2001):** VEGF receptor signal transduction. *Science STKE*; 112 (RE21): 1-17.
- Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM and Gordon KB (2010):** Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. *J Am Acad Dermatol*; 62(1):114-35.
- Milavec-Puretić V, Mance M, Ceović R and Lipozenčić J (2011):** Drug induced psoriasis *Acta Dermatovenerol Croat.* ;19(1):39-42.
- Mobini N, Toussaint S and Kamino H (2005):** Noninfectious erythematous, popular and squamous diseases. In: *Lever's histopathology of the skin*. By: Elder DE, Elintzas R, Johnson BL and Murphy GF. Lippincott Williams and Wilkins pub. 9th eds.; vol 1, chapt 7, pp. 179-214.
- Morris A, Rogers M and Fischer G (2001):** Childhood psoriasis: A clinical review of 1262 cases. *Pediatr Dermatol*; 18:188-98.

- Moscaliuc M, Heller M, Lee E, and Koo J (2012):** Goeckerman therapy: a very effective, yet often forgotten treatment for severe generalized psoriasis. *Journal of Dermatol Treat*; 23(3):160-165.
- Muhleisen B, Buchi S, Schmidhauser S, Jenewein J, French LE and Hofbauer GFL (2009):** Pictorial Representation of Illness and Self Measure (PRISM): A novel visual instrument to measure quality of life in dermatological inpatients. *Archives of dermatology*; 145(7):774-80.
- Mukhopadhyay D, Knebelmann B, Cohen HT, Ananth S and Sukhatme VP (1997):** The von Hippel-Lindau tumor suppressor gene product interacts with Sp1 to repress vascular endothelial growth factor promoter activity. *Mol. Cell Biol.*; 17: 5629–5639.
- Muller-Hermelink N., Braumuller H. and Pichler B. (2008):** TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinoma. *Cancer Cell*; 13:507–518.

(N)

- Naldi L and Griffiths CEM (2007):** Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. *Br J Dermatol*; 52: 597-615.

- Nestle FO, Di Meglio P, Qin J-Z and Nickoloff BJ (2009):** Skin immune sentinels in health and disease. *Nat. Rev. Immunol*; 9: 679–691.
- Neufeld G, Cohen T, Shrager N, Lange T, Kessler O and Herzog Y (2002):** The neuropilins: multifunctional semaphorin and VEGF receptors that modulate axon guidance and angiogenesis. *Trends Cardiovasc. Med*; 12, 13–19.
- Nielsen HJ, Christensen IJ and Svendsen MN (2002):** Elevated plasma levels of vascular endothelial growth factor and plasminogen activator inhibitor-1 decrease during improvement of psoriasis. *Inflamm. Res*; 51:563–567.
- Nofal A, Al-Makhzangy I, Attwa E, Nassar A and Abdalmoati A (2009):** Vascular endothelial growth factor in psoriasis: an indicator of disease severity and control. *J Eur Acad Dermatol Venereol*; 23: 803–806.
- Norris A (2005):** Mechanisms of action of topical therapies and the rationale for combination therapy, *J. Am. Acad. Dermatol*; 53(1):17-25.
- Norsgaard H, Svensson L, Hagedorn PH, Moller K, Olsen GM, Labuda T (2012):** Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model. *Br. J. Dermatol.*;166(3) : 649–652.

Ojunsota OO, Stewart WB and Mihacik V (2000): Neuronal VEGF expression correlates with angiogenesis in postnatal developing rat brain. *Brain Res Dev. Brain*; 119:139-153.

Olofsson B, Korpelainen E and Pepper MS (1998): Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator in endothelial cells. *Proc Natl Acad Sci USA*; 95:1170-11714.

(P)

Park JE, Chen HH, Winer J, Houck KA and Ferrara N (1994): Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. *J. Biol. Chem*; 269: 25646-25654.

Peter CMY and Joost S (2008): In: *Dermatology*. Bologna, JL Joseph L, Jorizzo MD, Ronald P, Rapini MD (eds). Elsevier, Mosby; 1: 115-25.

Pierce EA, Avery RL, Foley ED, Aiello LP and Smith LE (1996): Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. *Proc. Natl. Acad. Sci. USA*; 92: 905–909.

Pitzalis C, Cauli A and Pipitone (1996): Cutaneous lymphocyte antigen– positive T lymphocytes preferentially migrate to the skin but not to the joint in psoriatic arthritis. *Arthritis Rheum*; 39:137-45.

Pont-Giralt M, Gimenez-Arnau AM, Pujol RM and Santamaria-Babi LF (2006): Circulating CLA (+) T cells from acute and chronic

psoriasis patients manifest a different activation state and correlation with disease severity and extension. *J Invest Dermatol*; 126:227-8.

(R)

Rosmarin DM, Lebwohl M, Elewski BE and Gottlieb AB (2010): Cyclosporine and Psoriasis: National Psoriasis Foundation Consensus Conference. *J Am Acad Dermatol* ; 62:838–53.

Rottman JB, Smith TL, Ganley KG, Kikuchi T, and Krueger JG (2001): Potential role of the chemokine receptors CXCR3, CCR4, and the integrin α E β 7 in the pathogenesis of psoriasis vulgaris. *Lab Invest*; 81:335-47.

Roya H, Bhardwaja S and Yla-Herttuala S (2006): Biology of vascular endothelial growth factors. *FEBS Lett*; 580: 2879–2887.

Rozenblit M and Lebwohl M (2009): New biologics for psoriasis and psoriatic arthritis. *Dermatol Ther* ;22(1):56-60.

(S)

Sanz LP (2007): Novalities in Dermatology. Psoriasis, a systemic disease. *Actas Dermosifiliogr*; 98: 396-402.

Scalia R, Booth G and Lefer DJ (1999): Vascular endothelial growth factor attenuates leukocyte-endothelium interaction during acute endothelial dysfunction. *FASEB J*; 13:1039.

- Schmitt J and Wozel G (2005):** The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. *Dermatology*; 210(3): 194-199.
- Schneider LA, Hinrichs R and Scharffetter-Kochanek K (2008):** Phototherapy and photochemotherapy. *Clin. Dermatol*; 26: 464-476.
- Schon M and Boehncke W (2005):** Psoriasis. *N Engl J Med*; 352:1899-1912.
- Schopf RE, Aust H and Knop J (2002):** Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. *J Am Acad Dermatol*; 46:886–91.
- Shelling ML and Kirsner RS (2010):** Failure to counsel patients with psoriasis to decrease alcohol consumption (and smoking). *Arch Dermatol* ; 146(12):1370.
- Shibuya M (2012):** Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis. A Crucial Target for Anti- and Pro-Angiogenic Therapies. *Genes & Cancer*; 2 (12):1097-1105.
- Shibuya M and Claesson-Welsh L (2006):** Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. *Exp. Cell Res*; 312:549–560.
- Siaw-Cheok L, Esha D, Srikumar C, Shew-Fung W, Nagarajah L., Najeeb S and Adawiyah J (2012):** Differential expression of the angiogenesis growth factors in psoriasis vulgaris. *BMC Research Notes*; 5:201.
- Siemeister G, Schirner M, Reusch P, Barleon B, Marme D, and Martiny-Baron G (1998):** An antagonistic vascular endothelial

growth factor (VEGF) variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells. Proc. Natl. Acad. Sci. USA; 95:4625-4629.

Simonetti O, Lucarini G and Goteri G (2006): VEGF is likely a key factor in the link between inflammation and angiogenesis in psoriasis: results of an immunohistochemical study. Int J immunopathol Pharmacol; 19: 751- 670.

Simpson D and Noble S (2005): Tacrolimus ointment: a review of its use in atopic dermatitis and its clinical potential in other inflammatory skin conditions. Drugs;65(6):827-58.

Sims J (2012): IL-36 stimulates Th1 responses and is implicated in humanpsoriasis. Cytokine ;59(3): 492.

Sismanopoulos N, Delivanis DA, Alysandratos K, Angelidou A, Vasiadi, Therianou A and Theoharis C (2012): IL-9 Induces VEGF Secretion from Human Mast Cells and IL-9/IL-9 Receptor Genes Are Overexpressed in Atopic Dermatitis. PLoS One; 7(3): 33271.

Skobe M, Rockwell P, Goldstein N, Vosseler S, and Fusenig NE (1997): Halting angiogenesis suppresses carcinoma cell invasion. Nature Med; 3: 1222–1227.

Soker S, Miao H, Nomi M, Takashima S and Klagsbrun, M (2002): VEGF165 mediates formation of complexes containing VEGFR-2 and neuropilin-1 that enhance VEGF165-receptor binding. J. Cell. Biochem; 85: 357–368.

Steinman RM, Hawiger D and Nussenzweig MC (2003): Tolerogenic dendritic cells. Annu Rev Immunol; 21: 685-711.

- Stern DK, Creasey AA, Quijije J and Lebwohl MG(2011):** UV-A and UV-B Penetration of Normal Human Cadaveric Fingernail Plate. Arch Dermatol; 147(4):439-41.
- Stern RS (1995):** Epidemiology of psoriasis. Dermatol Clin; 13: 717-722.
- Stern RS (2007):** Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med; 357:682.
- Stone J, Itin A, Alon T, Peer J, Gnessin H, Chanling T and Keshet E (1995):** Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J. Neurosci; 15: 4738- 4747.
- Sweeney CM, Tobin AM and Kirby B (2011):** Innate immunity in the pathogenesis of psoriasis. Arch Dermatol Res; 303(10):691-705.
- Szepietowski JC, Morita A and Tsuji T (2002):** Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med. Hypotheses; 58:167-170.

(T)

- Takei Y, Talashima S, Ohyu J, Takami T, Miyajima T and Hoshika A (1999):** Effects of nitric oxide synthase inhibition on the cerebral circulation and brain damage kainic acid induced seizures in newborn rabbits. Brain Dev.; 21:253-9.

Toichi E, Tachibana T and Furukawa F (2000): Rapid improvement of psoriasis vulgaris during drug induced agranulocytosis. J Am Acad Dermatol; 43: 391-95.

Tran J, Master Z, Yu J, Dumont D and Kerbel R (2002): A role of survivine in chemoresistance of endothelial cells mediated by VEGF. Cell biology;99(7):4349-4354.

Traub M and Marshall K (2007): Psoriasis--pathophysiology, conventional, and alternative approaches to treatment. Altern Med Rev ; 12(4):319-30.

(U)

Uhlenhake EE and Mehregan DA (2012): Managing psoriasis: What's best for your patient? The journal of family practice; 61(7): 402-451

(V)

Van de Kerkhof P and Schalkwijk J (2008): Psoriasis. In Dermatology (second edition). Bologna J.L., Jorizzo J.L. and Rapini R.P. (eds). Mosby. Spain; Pp 113-135.

Van Noort JM, Bsibsi M, Nacken P, Gerritsen WH and Amor S (2012): The link between small heatshockproteins and the immune system . The International Journal of Biochemistry & Cell Biology;44(10):1670–1679.

(W)

- Walters IB, Ozawa M and Cardinale I (2003):** Narrowband (312-nm) UV-B Suppresses Interferon γ and Interleukin (IL) 12 and Increases IL-4 Transcripts. *Arch. Dermatol*; 139: 155-161.
- Warren RB, Smith RL, Campalan Ei, Eyre S, Smith CH, Barke Jr, Worthington J and Griffiths CEM (2009) :** Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms, *Br J Dermatol*; 160(2): 438–441.
- Wieder T, Braumuller H, Kneilling M, Pichler B and Rocken M (2008):** T cell-mediated help against tumors. *Cell Cycle*; 7:2974–2977.
- Wise LM, Veikkola T and Merce AA (1999):** Vascular endothelial growth factor (VEGF)-like protein binds to VEGFR2 and neuropilin-1. *proce Nal Acad Sci USA*; 96:3071.
- Witman PM (2001):** Topical therapies for localized psoriasis. *Mayo Clin Proc*; 76: 943- 949.
- Wu L and Van Kaer L (2009):** Natural killer T cells and autoimmune disease. *Curr Mol Med*; 9(1):4-14.

(X)

- Xia YP, Li B, Hylton D, Detmar M, Yancopoulos GD and Rudge JS (2003):** Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. *Blood*; 102:161–168.

(Y)

Yamada Y, Nezu J and Shimane M (1997): Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. *Genomics*. 42: 483-488.

Yang R (1996): Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. *J. Cardiovasc. Pharmacol.*; 27: 838-844.

Young HS, Summers AM and Read IR (2006): Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. *J. Invest. Dermatol.*; 126:453–459.

(Z)

Zablotna M, Sobjanek M, Nedoszytko B, Lange M, Kozicka D, Glen J, Roszkiewicz J(2011): Association of psoriasis with the VEGF gene polymorphism in the northern Polish population. *J Eur Acad Dermatol Venereol*; doi: 10.1111/j.1468-3083.2011.04393.x.

Zanolli M (2004): Phototherapy arsenal in the treatment of psoriasis. *Dermatol. Clin.*; 22(2): 397-406.